NCT07879131Not yet recruiting
A Mobile App to Support Mood, Daily Routines and Medication Adherence in Adults With Severe Mental Illness
Effectiveness of MoodSync: A Just-in-Time Dual Mobile Application for Mood Monitoring, Social Rhythm Regulation, Medication Adherence, and Relapse Prevention Among Patients With Severe Mental Illness: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn whether MoodSync, a mobile application for patients and their family caregivers, improves mood stability, medication adherence, daily functioning and early detection of relapse warning signs in adults with severe mental illness in Bahrain. The main question it aims to answer is: Does MoodSync plus standard care improve manic symptoms, medication adherence, practical and social functioning, and early warning signs more than standard care alone? Participants will be randomly assigned to MoodSync plus standard care or standard care alone. MoodSync participants will use the patient app for 12 weeks for daily mood check-ins, sleep and activity tracking with a wearable device, medication reminders, daily-routine (social rhythm) support and early warning-sign reporting. A nominated family caregiver may use the linked caregiver app. All participants continue standard care and complete questionnaires before and after the intervention period. Research hypothesis: \* Patients who use MoodSync will show greater improvement in mood symptoms, medication adherence, practical and social functioning, and relapse-related outcomes than patients receiving standard care alone.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 10 Oct 2026
- Start date
- Nov 2026
- Primary completion date
- Sept 2027
- Lead sponsor
- Alexandria University
- Diseases
- Schizophrenia, Depression, Bipolar disorder
- NCT number
- NCT07879131
What you commit to
- Study type: Interventional
- Planned participants: 60
- From Nov 2026 to the primary completion date, Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Acute psychiatric crisis at the time of recruitment
- Severe cognitive impairment preventing use of the application
Other
- Inability to provide informed consent
- No access to a compatible mobile device, unless one is provided by the project
- Family caregivers (intervention group, optional): adult family member nominated by the participant, who gives separate written informed consent.
Who the study is looking for
- Adults aged 18 years or older
- Diagnosis of a severe mental illness (bipolar I or II disorder, schizophrenia, schizoaffective disorder, or major depressive disorder) according to DSM-5-TR, confirmed by the treating psychiatrist
- Clinically stable, defined as no psychiatric hospital admission in the previous 3 months
- Receiving care at a participating mental health service
- Able to use a smartphone application
- Able to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Psychiatric Hospital, Government Hospitals Coordinator of this site? Confirm its status | Manama | Bahrain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.